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CONCLUSIONS OF THE CONSULTATION 
The World Health Organization (WHO) convened an 
expert consultation to review new evidence on the 
use of antiretroviral drugs to prevent mother-to-child 
transmission of HIV (PMTCT) as well as on-going 
research likely to yield new data in the next 6 to 12 
months. A particular focus was placed on reviewing 
data on interventions to reduce transmission of HIV 
through breastfeeding. The purpose of the 
consultation was to analyse these findings and 
identify gaps in the current evidence base, in order to 
clarify the necessary steps and timelines for the 
revision of WHO guidelines on PMTCT. 
Background 
About 370,000 children younger than 15 years of age 
worldwide become infected with HIV in 2007
1
. The 
overwhelming majority of these children are infected 
as a result of transmission of the virus from HIV-
infected mothers during pregnancy, childbirth or 
breastfeeding. Most of these mothers and children 
live in sub-Saharan Africa where infant, child and 
maternal mortality rates are generally high.  
The 2006 WHO guidelines on antiretroviral (ARV) 
drugs for treating pregnant women living with HIV 
and preventing HIV infections in infants
2
 take account 
of the intimate relationship between maternal health 
and child survival. Early identification of pregnant 
women living with HIV who require antiretroviral 
therapy (ART) for their own health and successful 
initiation of such drugs will improve the health and 
survival of mothers and significantly reduce infant 
and child mortality. Data from cohorts in Europe and 
North America demonstrate what can be achieved in 
well-resourced health systems and communities. 
Providing HIV-infected pregnant women with ART or 
combination ARV prophylaxis according to respective 
eligibility criteria has substantially reduced the risk of 
infants becoming infected during pregnancy and 
delivery. When combined with elective Caesarean 
section and avoidance of all breastfeeding, these 
interventions have reduced the risk of HIV 
transmission to infants to approximately 1%. In 
resource-limited settings, similarly low rates of 
peripartum transmission (2-5%) have been reported 
in some research and pilot programmes. 
                                                    
1
 UNAIDS. Global AIDS Epidemic Report 2008 
2
WHO. Antiretroviral drugs for treating pregnant women and 
preventing HIV infection in infants: towards universal access. 
Recommendations for a public health approach. 2006.  
http://www.who.int/hiv/pub/guidelines/pmtct/en/index.html  
Unfortunately the results of PMTCT services in many 
national programmes, have been less encouraging. 
Low rates of HIV testing among pregnant women, 
lack of availability and access to PMTCT services, 
and difficulties integrating PMTCT interventions 
within existing maternal and child health (MCH) 
services compounded by human resource constraints 
have contributed to the slow pace of expansion of 
PMTCT coverage. Countries’ transition from 
providing only single dose nevirapine (sdNVP) to the 
mother during labour and the infant after birth to more 
efficacious combination prophylaxis regimens has 
also been slow. In addition, reducing the risk of 
postnatal transmission via breastfeeding has 
remained a significant challenge. As a result there 
has been a limited reduction in the number of 
paediatric HIV infections.  
Meeting participants and content 
Participants of the WHO expert consultation included 
researchers and programme experts. Together they 
reviewed the results of studies on whether ARVs 
delivered to HIV-infected breastfeeding mothers, or to 
their infants during the period of breastfeeding, 
reduce the risks of transmission and allow infants to 
gain the benefits of breastfeeding and thereby 
improve HIV-free survival. The designs and 
preliminary results of other ongoing or planned 
studies were also reviewed. See table below. 
WHO process of developing or updating guidelines 
includes the systematic review of randomized and 
observational studies and programme data to assess 
the efficacy and effectiveness of interventions
3
.  New 
recommendations are based on thorough review of 
evidence of efficacy and safety of interventions, 
modelling of the cost and impact of different 
scenarios to assess the advantages of any given 
intervention against its potential for harm, and 
detailed assessments of its acceptability, cost and 
feasibility for delivery within health care systems. 
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Studies reported in peer-reviewed journals, international conferences or that are ongoing / planned 
Studies that have been reported or presented Ongoing 
AMATA Observational cohort of HIV+ mothers given 
ARVs antenatally and while breastfeeding 
BAN RCT* of triple ARVs to mothers or NVP to 
infants during breastfeeding 
DREAM Observational cohort of HIV+ mothers given 
ARVs antenatally and while breastfeeding 
Kesho 
Bora 
RCT* of triple ARVs compared with short-
course ZDV+sdNVP to mothers during 
pregnancy and breastfeeding  
MITRA +  Observational cohort of HIV+ women given ART 
antenatally and while breastfeeding 
Mma Bana RCT* of two different triple- combination 
ARVs to mothers during pregnancy and 
breastfeeding 
KiBS Observational cohort of HIV1 mothers given 
ARVs antenatally and while breastfeeding 
HPTN 046 RCT* of NVP for 6m compared to 6wks to 
infants while breastfeeding 
Planned  MASHI RCT* of AZT to breastfeeding infants compared 




RCT* of 3TC compared to placebo for infants 
while breastfeeding 




RCT* of ARVs to mothers or infants during 
pregnancy and breastfeeding 
ZEBS RCT* of counselling of mothers for early 
cessation vs. continued breastfeeding 
SWEN RCT* of NVP for 6 wks compared with placebo 




ART to all pregnant women during pregnancy 
and while breastfeeding 
PEPI RCT* of NVP for 3 mo compared to placebo for 
infants while breastfeeding 
*RCT – Randomised controlled trial 
Outcomes of studies were reviewed in terms of: HIV transmission and HIV-free survival; resistance and subsequent responses to ART; 
feasibility of interventions; morbidity and mortality of infants who stop breastfeeding; birth outcomes; and harmonization of guidelines, in this 
case PMTCT guidelines, with WHO adult and paediatric treatment guidelines. 
 
The results of these studies are very promising and 
suggest that new intervention strategies may 
substantially lower the risk of HIV transmission to 
infants during pregnancy, delivery and breastfeeding.  
However, the evidence is insufficient to fully assess 
which interventions are the most effective, feasible 
and safe for mothers and infants if implemented 
within health care systems. Additional data will 
become available in the next nine months. WHO will 
actively collaborate with investigators to assess their 
significance in order to revise recommendations at 
the earliest appropriate time. 
The participants strongly recommended the following 
actions: 
In guideline development 
• WHO-recommended eligibility criteria for initiating 
ART for pregnant women own health be urgently 
reviewed with a view to earlier initiation; 
• WHO recommendations for infant ARV 
prophylaxis be urgently reviewed   
• Further simplifications of existing guidelines be 
considered in order to facilitate country 
implementation; 
In service delivery 
• PMTCT services prioritize identifying HIV-
infected pregnant women who fulfil current 
eligibility criteria for lifelong ART in order rapidly 
to initiate comprehensive treatment and care; 
• For HIV-infected pregnant women who do not 
fulfil these criteria, PMTCT services should work 
to provide WHO recommended PMTCT 
interventions that are more efficacious than 
sdNVP only; 
• HIV-infected mothers receive high quality 
counselling with respect to infant feeding options; 
• PMTCT services be fully integrated into MCH 
services and linked with HIV treatment sites; 
• Further work be conducted to address 
implementation problems that threaten the quality 
and impact of PMTCT services, beyond the 
choice of ARV regimens for therapy or 
prophylaxis; 
In research 
• Research continue in order to identify the most 
effective, safe and feasible interventions to 
prevent transmission of HIV to infants during 
pregnancy, childbirth and while breastfeeding; 
• Implementation research be conducted to learn 
how to deliver integrated PMTCT services more 
effectively and link with follow-up care and 
treatment of mothers and infants; 
• Monitoring and evaluation data be collected and 
reported to inform the feasibility and population 
impact of PMTCT interventions. 
A full revision of WHO recommendations for PMTCT 
is anticipated in mid-late 2009. 
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